Furthermore, this unique metabolic feature of CLL cells is driven by STAT3, an oncogenic pathway that endows CLL cells’ survival advantages by binding and activating the promotors of LPL (145, 146). The gene discussed is STAT3; the disease is B-cell chronic lymphocytic leukemia.